Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Managing Brain Metastases and Side Effects in Melanoma

July 14th 2016

Melanoma: BRAF/MEK Targeted Therapy

July 14th 2016

Need for Subgroup Analyses in Melanoma Trials

July 14th 2016

Disease Burden and First-Line Melanoma Treatment

July 14th 2016

Neoadjuvant Strategies in Melanoma

July 14th 2016

Immunotherapy in Advanced Melanoma

July 14th 2016

Initial Strategies in Advanced Melanoma

July 14th 2016

Validity of PD-L1 Testing in Melanoma

July 14th 2016

Mutations of Clinical Significance in Melanoma

July 14th 2016

Incorporating Prognostic Factors in Melanoma

July 14th 2016

The Biology of Advanced Melanoma

July 14th 2016

A Closer Look at Tumor Location Analyses in Colon Cancer

July 14th 2016

Tumor Locations in CRC

July 14th 2016

A Closer Look at FIRE-3 and CALGB/SWOG 80405

July 14th 2016

First-line Targeted Therapies in Metastatic CRC

July 14th 2016

Practical Application of Molecular Testing in CRC

July 14th 2016

Personalized Medicine in Colorectal Cancer

July 14th 2016

FDA Releases Draft Guidances on Next-Generation Sequencing

July 7th 2016

The FDA has issued two draft guidances that will provide regulatory oversight for the use of next-generation sequencing-based tests.

Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline Sequencing

July 6th 2016

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.